APA

Peyronnet B., Castel-Lacanal E., Roumiguie M., Even L., Marque P., Soulié M., Rischmann P. & Game X. (20180112). Intradetrusor injections of onabotulinum toxin A (Botox®) 300 U or 200 U versus abobotulinum toxin A (Dysport®) 750 U in the management of neurogenic detrusor overactivity: A case control study. : Neurourology and urodynamics.

Chicago

Peyronnet Benoit, Castel-Lacanal Evelyne, Roumiguie Mathieu, Even Lucie, Marque Philippe, Soulié Michel, Rischmann Pascal and Game Xavier. 20180112. Intradetrusor injections of onabotulinum toxin A (Botox®) 300 U or 200 U versus abobotulinum toxin A (Dysport®) 750 U in the management of neurogenic detrusor overactivity: A case control study. : Neurourology and urodynamics.

Harvard

Peyronnet B., Castel-Lacanal E., Roumiguie M., Even L., Marque P., Soulié M., Rischmann P. and Game X. (20180112). Intradetrusor injections of onabotulinum toxin A (Botox®) 300 U or 200 U versus abobotulinum toxin A (Dysport®) 750 U in the management of neurogenic detrusor overactivity: A case control study. : Neurourology and urodynamics.

MLA

Peyronnet Benoit, Castel-Lacanal Evelyne, Roumiguie Mathieu, Even Lucie, Marque Philippe, Soulié Michel, Rischmann Pascal and Game Xavier. Intradetrusor injections of onabotulinum toxin A (Botox®) 300 U or 200 U versus abobotulinum toxin A (Dysport®) 750 U in the management of neurogenic detrusor overactivity: A case control study. : Neurourology and urodynamics. 20180112.